{"product_id":"89bio-bcg-matrix","title":"89bio Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCurious where 89bio’s products land—Stars, Cash Cows, Dogs, or Question Marks? This preview teases the shifts and signals, but the full BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a strategic roadmap you can act on. Purchase the complete report for a ready-to-use Word analysis plus an Excel summary—clear insights to guide investment, product focus, and competitive moves without another minute of guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin in NASH\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePegozafermin, an FGF21 analog and 89bio's lead asset in NASH, shows strong clinical signals and sits in a NASH market projected to reach roughly $24B by 2030 with ~20% CAGR (2024 estimates). If momentum holds it behaves like a Star: high growth, leadership potential, and heavy R\u0026amp;D spend; maintaining funding for pivotal trials, payer groundwork, and KOL advocacy is pivotal. Protect the lead via smart trial design and a crisp safety narrative.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePegozafermin in SHTG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSHTG is urgent and visible as cardiometabolic risk climbs: NHANES estimates ~1.7% of US adults have triglycerides ≥500 mg\/dL (~4.4M people) and global diabetes prevalence exceeds 10%, amplifying demand for SHTG therapies. Early pegozafermin data show promising TG-lowering signals and unmet need places the program in the Star lane if execution remains tight. Double down on regulatory pathing and real-world evidence prep now. Build specialist awareness to lock in share later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFGF21 platform credibility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngineered FGF21 analog know‑how is scarce—fewer than 20 clinical‑stage FGF21 programs existed globally in 2024, making platform expertise highly valuable. Deep FGF21 platform capability can create a leadership halo across liver and metabolic care, a market projected above $30 billion by 2030 (2024 consensus). Continued publishing and presenting keeps 89bio owning the scientific conversation, attracting partners, talent, and capital.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory momentum: securing designations, clean FDA dialogues, and agreed clear endpoints accelerates 89bio’s competitive positioning in a fast-growing NASH\/rare liver space; smoother paths typically lead to share appreciation.\u003c\/p\u003e\n\u003cp\u003eMaintain proactive engagement and submission readiness to convert regulatory clarity into value; this strategy burns cash but materially thickens the regulatory moat.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003edesignations: priority review \/ breakthrough engagement\u003c\/li\u003e\n\u003cli\u003eclean dialogues: reduces endpoint risk\u003c\/li\u003e\n\u003cli\u003esubmission readiness: readiness drives timing\u003c\/li\u003e\n\u003cli\u003etrade-off: higher burn today, stronger moat tomorrow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKOL and trial network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eKOL and trial network\u003c\/h3\u003eHigh-performing sites and advocates are hard to replicate; in a hot NASH\/steatohepatitis market the KOL+site network functions as a Star asset, driving faster enrollment, higher retention and payer visibility. Nurture consistency, speed and patient access and scale footprint before competitors crowd the field.\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNetwork scarcity\u003c\/li\u003e\n\u003cli\u003eEnrollment velocity\u003c\/li\u003e\n\u003cli\u003eRetention advantage\u003c\/li\u003e\n\u003cli\u003eFirst-mover scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase 2 FGF21 shows strong NASH\/SHTG signals; markets: \u003cstrong\u003e$24B\u003c\/strong\u003e NASH, \u003cstrong\u003e$30B+\u003c\/strong\u003e metabolic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePegozafermin is a Star: strong Phase 2 signals in NASH\/SHTG, target markets ~$24B (NASH) and \u0026gt;$30B (metabolic) by 2030 (2024 estimates), ~20% CAGR, and SHTG prevalence ~1.7% US adults (~4.4M). Platform scarcity (\u0026lt;20 FGF21 programs in 2024) plus regulatory\/KOL momentum support leadership if execution and funding persist.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNASH market\u003c\/td\u003e\n\u003ctd\u003e$24B by 2030 (2024 est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFGF21 programs (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHTG US\u003c\/td\u003e\n\u003ctd\u003e1.7% (~4.4M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eIn-depth BCG analysis of 89bio's products, identifying Stars, Cash Cows, Question Marks and Dogs with clear investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix that maps 89bio units into clear quadrants, cutting analysis time and easing exec decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed therapies yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNo true Cash Cow—clinical-stage 89bio (ETNB) has no marketed therapies or steady low‑growth revenue as of 2024. Name this explicitly to avoid strategy drift. Map how pegozafermin can mature into a Cash Cow post‑launch (pricing, market access, uptake timelines) and set cost discipline now so target margins materialize on schedule.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture NASH label durability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf approved and the market matures, sustained share turns into cash generation; that's the classic Cow: leader, low incremental promo and reliable cash flow. As of 2024 there are no FDA‑approved pharmacologic therapies for NASH and NAFLD affects about 25% of adults globally, supporting a large addressable market. Prepare lifecycle management, real‑world outcomes and coverage renewals and lock in guideline inclusion to cement positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture SHTG chronic scripts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFuture SHTG chronic scripts could produce stable repeat prescriptions with modest growth once established; chronic diseases drive 90% of US healthcare costs (CDC, 2024) supporting predictable demand. Efficiency and adherence programs — medication adherence averages ~50% in developed countries (WHO) — can materially boost margin. Early investment in patient support and streamlined distribution reduces churn and targets steady net revenue with minimal surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform royalties (post-partner)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSelect partnered deals can yield low‑growth, high‑margin royalty streams consistent with Cash Cow dynamics; typical pharma royalty rates range around 10–20% and require minimal promotion spend, supporting \u0026gt;60–70% contribution margins on royalty income. Structure upfront milestones and durable royalty tiers now to secure downstream stability and retain rights where economics are strongest.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eroyalty rate: 10–20%\u003c\/li\u003e\n\u003cli\u003emargin profile: \u0026gt;60% contributn\u003c\/li\u003e\n\u003cli\u003emilestones: align for long‑term streams\u003c\/li\u003e\n\u003cli\u003erights: prioritize high‑economics territories\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing efficiency at scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManufacturing efficiency at scale: as biologics scale, COGS can decline roughly 20–30% and batch yields improve, swelling operating cash flow—critical for 89bio as it transitions assets toward commercial maturity; treat ops excellence as a future Cash Cow and prioritize supplier lock-ins, validated second sources, and automated QA to protect margin.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLock reliable suppliers\u003c\/li\u003e\n\u003cli\u003eValidate second sources\u003c\/li\u003e\n\u003cli\u003eAutomate QA\u003c\/li\u003e\n\u003cli\u003eSmall opex tweaks can swing cashflow materially\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed product in 2024 - NASH therapy must nail price, access to hit \u0026gt;60% margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNo Cash Cow in 2024—89bio has no marketed products; pegozafermin must hit pricing, access and margin targets to become one.\u003c\/p\u003e\n\u003cp\u003eNASH\/NAFLD ~25% adult prevalence globally (2024); guideline inclusion and payer coverage drive steady uptake.\u003c\/p\u003e\n\u003cp\u003ePartner royalties 10–20%, scaled COGS −20–30% → potential \u0026gt;60% contribution margins; secure suppliers, automate QA, patient support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNAFLD prevalence\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS decline est.\u003c\/td\u003e\n\u003ctd\u003e20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003e89bio BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact BCG Matrix report you'll receive after purchase. No watermarks or demo content—just a fully formatted, editable document built for strategic clarity. Crafted by strategy pros with market-backed analysis, it's ready to print, present, or plug into your planning. Once bought, the same file is yours to download and use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674687062393,"sku":"89bio-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/89bio-bcg-matrix.png?v=1755793245","url":"https:\/\/portersfiveforce.com\/products\/89bio-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}